Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy

Clinical Liver Disease - United Kingdom
doi 10.1002/cld.781
Full Text
Abstract

Available in full text

Categories
Hepatology
Date
Authors
Publisher

Wiley

Related search

Two Cases of Hepatocellular Carcinoma Occurring Immediately After Direct-Acting Antiviral Agents Against Hepatitis C Virus

Internal Medicine
Internal MedicineMedicine
2019English

No Evidence for Higher Rates of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment: A Meta-Analysis

Hepatoma Research
2019English

Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma

Cancers
Cancer ResearchOncology
2019English

Predictors of Hepatocellular Carcinoma After Hepatitis C Virus Eradication Following Direct-Acting Antiviral Treatment: Relationship With Serum Zinc

Journal of Clinical Biochemistry and Nutrition
MedicineNutritionClinical BiochemistryDietetics
2020English

De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era

Hepatology
MedicineHepatology
2018English

Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy

Gastroenterology
HepatologyGastroenterology
2018English

The Risk of Hepatocellular Carcinoma Is Increased in Hepatitis C Virus Patients Treated With Interferonfree Direct-Acting Antiviral-Based Therapy: True or False?

Biomedical Journal of Scientific & Technical Research
2018English

The Frequency of Occurrence of Hepatocellular Carcinoma After Direct Antiviral Therapy in Hepatitis C Virus Patients

Pakistan Journal of Medical Sciences
Medicine
2019English

Direct-Acting Antiviral Therapy for HCV Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

Gastroenterology
HepatologyGastroenterology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy